Literature DB >> 23797056

In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals.

Kamrun Nahar1, Nilesh Gupta, Robert Gauvin, Shahriar Absar, Brijeshkumar Patel, Vivek Gupta, Ali Khademhosseini, Fakhrul Ahsan.   

Abstract

Delivery of therapeutic agents via the pulmonary route has gained significant attention over the past few decades because this route of administration offers multiple advantages over traditional routes that include localized action, non-invasive nature and favorable lung-to-plasma ratio. However, assessment of post administration behavior of inhaled pharmaceuticals-such as deposition of particles over the respiratory airways, interaction with the respiratory fluid and movement across the air-blood barrier-is challenging because the lung is a very complex organs that is composed of airways with thousands of bifurcations with variable diameters. Thus, much effort has been put forward to develop models that mimic human lungs and allow evaluation of various pharmaceutical and physiological factors that influence the deposition and absorption profiles of inhaled formulations. In this review, we sought to discuss in vitro, in vivo and ex vivo models that have been extensively used to study the behaviors of airborne particles in the lungs and determine the absorption of drugs after pulmonary administration. We have provided a summary of lung cast models, cascade impactors, noninvasive imaging, intact animals, cell culture and isolated perfused lung models as tools to evaluate the distribution and absorption of inhaled particles. We have also outlined the limitations of currently used models and proposed future studies to enhance the reproducibility of these models.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug absorption from lung; Imaging; In vitro models; Isolated perfused lung; Particle deposition; Pulmonary drug delivery

Mesh:

Substances:

Year:  2013        PMID: 23797056     DOI: 10.1016/j.ejps.2013.06.004

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  23 in total

Review 1.  Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.

Authors:  Cheng Loong Ngan; Azren Aida Asmawi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

2.  Aerosol delivery into small anatomical airway model through spontaneous engineered breathing.

Authors:  Chun-Kai Lin; Yuan-Yuan Hsiao; Pulak Nath; Jen-Huang Huang
Journal:  Biomicrofluidics       Date:  2019-08-07       Impact factor: 2.800

3.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

4.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

5.  Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil.

Authors:  Thi-Tram Nguyen; Eun-Jin Yi; Kyu-Mok Hwang; Cheol-Hee Cho; Chun-Woong Park; Ju-Young Kim; Yun-Seok Rhee; Eun-Seok Park
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

6.  Medication Tracking: Design and Fabrication of a Dry Powder Inhaler with Integrated Acoustic Element by 3D Printing.

Authors:  Yongquan Li; Adam Bohr; Henrik Jensen; Jukka Rantanen; Claus Cornett; Moritz Beck-Broichsitter; Johan Peter Bøtker
Journal:  Pharm Res       Date:  2020-01-21       Impact factor: 4.200

7.  Human Airway Primary Epithelial Cells Show Distinct Architectures on Membrane Supports Under Different Culture Conditions.

Authors:  Kyoung Ah Min; Gus R Rosania; Meong Cheol Shin
Journal:  Cell Biochem Biophys       Date:  2016-01-27       Impact factor: 2.194

8.  Liposomal Aerosols of Nitric Oxide (NO) Donor as a Long-Acting Substitute for the Ultra-Short-Acting Inhaled NO in the Treatment of PAH.

Authors:  Kamrun Nahar; Jahidur Rashid; Shahriar Absar; Fahad I Al-Saikhan; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2016-04-05       Impact factor: 4.200

Review 9.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

Review 10.  Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.

Authors:  Arbel Artzy-Schnirman; Sivan Arber Raviv; Ofri Doppelt Flikshtain; Jeny Shklover; Netanel Korin; Adi Gross; Boaz Mizrahi; Avi Schroeder; Josué Sznitman
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.